Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

NCT03746704 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Advanced PD-L1 Positive Malignancies

Interventions

DRUG: 89Zr˗DFO˗REGN3504

Sponsor

Regeneron Pharmaceuticals